EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae

Linxin Yao iD, Tingli Tian, Danyang Zou, Xinying Lu, Nanyan Jiang, Xin Feng, Tong Zheng, Zhuojun Tang, Yi Lin, Zhen Ning, Jianping Jiang iD, Meiping Ye iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01706-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Linxin Yao und 12 weiteren Autor:innen. Beteiligte Einrichtung: STD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although gepotidacin is a promising oral candidate for treating multidrug-resistant Neisseria gonorrhoeae , its resistance mechanisms and clinical implications remain poorly understood. In this study, we collected 989 clinical N. gonorrhoeae isolates from 33 hospitals in Shanghai, China (2022–2024). Antimicrobial susceptibility testing showed that gepotidacin exhibited high in vitro activity with MIC 50 and MIC 90 of 0.5 and 1 μg/mL, respectively. Further investigation identified that elevated gepotidacin MICs were significantly associated with substitutions at GyrA position 92/95 and ParC position 86/87, including GyrA A92P (odds ratio [OR], 4.25; 95% confidence interval [CI], 2.61–6.94) and D95Y (OR, 4.61; 95% CI, 2.82–7.54), as well as ParC D86N (OR, 3.12; 95% CI, 1.99–4.90) and S87N (OR, 5.92; 95% CI, 3.63–9.64). Substitution combinations analyses revealed that GyrA D95A plus ParC D86N, GyrA A92P/D95Y plus ParC S87N, GyrA D95A plus ParC S87N, and GyrA D95G plus ParC D86N were significantly associated with elevated gepotidacin MICs. Notably, these high-risk substitutions were enriched in international clones ST7363 and ST8123. In vitro induction experiments demonstrated a stepwise resistance trajectory: from initial diverse QRDR mutations to an intermediate state with GyrA A92P/D95Y, followed by ParC D86N and GyrA A92T/D95A, culminating in high-level resistance, with MICs all reaching 64 μg/mL. We also found that the strain with preexisting GyrA D95A and ParC D86N more readily acquired A92T and developed high-level resistance under gepotidacin exposure. Our study highlights key mutational patterns and clonal backgrounds that promote gepotidacin resistance, emphasizing the need for optimized dosing strategies as well as targeted molecular surveillance to preserve its effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeAnti-Bacterial AgentsMicrobial Sensitivity TestsDNA GyraseHumansDrug Resistance, Multiple, BacterialDNA Topoisomerase IVGonorrheaMutationDrug Resistance, BacterialChinaAcenaphthenesHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Neisseria gonorrhoeaeParC D86Nantimicrobial resistancegepotidacinstepwise evolution

Substanzen

Anti-Bacterial AgentsgepotidacinDNA GyraseDNA Topoisomerase IVAcenaphthenesHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • STD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Division of Tuberculosis and HIV/AIDS Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Linxin Yao, Jianping Jiang, Meiping Ye, Pingyu Zhou

Förderung

  • Natural Science Foundation of Shanghai
  • National Natural Science Foundation of China

Zitieren

APA

Yao, L., Tian, T., Zou, D., Lu, X., Jiang, N., Feng, X., Zheng, T., Tang, Z., Lin, Y., Ning, Z., Jiang, J., Ye, M., & Zhou, P. (2026). Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01706-25

Vancouver

Yao L, Tian T, Zou D, Lu X, Jiang N, Feng X, et al. Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01706-25

BibTeX
@article{Yao2026,
  author = {Yao, Linxin and Tian, Tingli and Zou, Danyang and Lu, Xinying and Jiang, Nanyan and Feng, Xin and Zheng, Tong and Tang, Zhuojun and Lin, Yi and Ning, Zhen and Jiang, Jianping and Ye, Meiping and Zhou, Pingyu},
  title = {Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01706-25}
}
Kostenlos starten →